Asco 2019 event analyser – low-key meeting belies some huge stock moves
Puma gives investors something to celebrate at last
Drug Approvals for the 2 Most Common Types of Cancer in the Last 2 Years
14 years after floating on Nasdaq, and with a strategic rebranding as well as $2.4bn of accumulated losses under its belt, Alnylam on Friday achieved its proudest milestone yet: its first ever US approval. Patisiran is now the world’s first RNAi drug. So far so bullish. But history suggests that the group’s honeymoon might be … Συνεχίστε να διαβάζετε After Alnylam’s solo maiden launch, here comes the tricky bit.